Juq-016

| Model | Dosing Regimen | Primary End‑point | Outcome | |-------|----------------|-------------------|---------| | APP/PS1 transgenic mice (AD) | 10 mg kg⁻¹ PO daily, 3 mo | Amyloid‑β plaque load (Thioflavin‑S) | ↓ 44 % vs. vehicle (p < 0.001) | | Tau P301S mice (FTD) | 15 mg kg⁻¹ PO BID, 2 mo | Phospho‑tau (AT8) immunoreactivity | ↓ 38 % vs. vehicle (p < 0.01) | | 5xFAD mice (early‑stage AD) | 5 mg kg⁻¹ PO QD, 1 mo | Morris water maze escape latency | Improved by 27 % (p < 0.05) | | LPS‑induced neuroinflammation (C57BL/6J) | Single 20 mg kg⁻¹ PO, 24 h | CSF IL‑1β levels | ↓ 63 % vs. LPS alone (p < 0.001) | | Human iPSC‑derived microglia | 0.1–1 µM, 48 h | Phagocytosis of pHrodo‑Aβ | ↑ 2.3‑fold (EC₅₀ ≈ 0.32 µM) |

Key observations

If JUQ-016 refers to a non-device context, adapt the relevant sections: JUQ-016

| Upcoming Feature | Expected Release | Benefit | |------------------|------------------|---------| | Multimodal Vision AI | Q4 2026 | Detect surface defects in real time, integrate with robotic pick‑and‑place. | | Supply‑Chain Digital Twin Sync | Q2 2027 | Align production schedules with upstream logistics for “end‑to‑end” visibility. | | Federated ESG Scoring | Q3 2027 | Automatic ESG metric calculation across multiple plants, standardized for investors. | | Voice‑Activated Operator Interface | Q1 2028 | Hands‑free workflow adjustments, boosting safety and ergonomics. | | Model | Dosing Regimen | Primary End‑point